Elite Pharmaceuticals Inc (ELTP) Financial Statements (2024 and earlier)

Company Profile

Business Address 165 LUDLOW AVENUE
NORTHVALE, NJ 07647
State of Incorp. NJ
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
3/31/2023
12/31/2022
MRQ
3/31/2022
3/31/2021
3/31/2020
3/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,83217,9098,5353,1931,1322,278
Cash and cash equivalents7,83217,9098,5353,1931,1322,278
Receivables3,0955,5463,0583,4964,1071,322
Inventory, net of allowances, customer advances and progress billings9,5518,6026,7415,0134,1424,516
Inventory9,5518,6026,7415,0134,1424,516
Other undisclosed current assets1,0331,108527493870741
Total current assets:21,51033,16518,86112,19510,2518,857
Noncurrent Assets
Operating lease, right-of-use asset13191,032215363
Property, plant and equipment10,42610,2305,9536,6497,2288,444
Intangible assets, net (including goodwill)6,3416,6346,6346,6346,6346,634
Intangible assets, net (excluding goodwill)6,3416,6346,6346,6346,6346,634
Restricted cash and investments412497497497  
Deferred income tax assets2,1722,1722,172  
Other noncurrent assets     480468
Other undisclosed noncurrent assets21     
Total noncurrent assets:19,38619,55116,28813,99514,70515,545
TOTAL ASSETS:40,89652,71635,14926,18924,95724,402
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,4956,1486,1315,2086,3995,089
Interest and dividends payable78  
Accounts payable2,4471,4721,4319301,5781,375
Accrued liabilities5,0484,6764,6934,2714,8213,714
Deferred revenue13131313180
Debt3114713544112,061654
Other undisclosed current liabilities1521196180 1,163
Total current liabilities:7,8346,6546,6945,8138,6406,906
Noncurrent Liabilities
Long-term debt and lease obligation3,56215,4892,2251,7801,9682,127
Long-term debt, excluding current maturities3,56215,4891,3891,7411,8002,127
Liabilities, other than long-term debt5413981,00883941,246
Deferred revenue1922324659
Due to related parties     1,200
Other liabilities   39383546
Operating lease, liability   83639167
Derivative instruments and hedges, liabilities522376937   
Other undisclosed noncurrent liabilities    2,3623,5992,727
Total noncurrent liabilities:4,10215,8873,2334,2255,6616,100
Total liabilities:11,93622,5429,92710,03814,30113,006
Temporary equity, carrying amount      13,904
Equity
Equity, attributable to parent28,96030,17525,22216,15210,656(2,508)
Preferred stock     13,904 
Common stock1,0141,0141,0111,009841825
Treasury stock, value(307)(307)(307)(307)(307)(307)
Additional paid in capital164,751164,736164,577164,407150,265148,780
Accumulated deficit(136,498)(135,269)(140,060)(148,958)(154,046)(151,806)
Total equity:28,96030,17525,22216,15210,656(2,508)
TOTAL LIABILITIES AND EQUITY:40,89652,71635,14926,18924,95724,402

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
3/31/2023
12/31/2022
TTM
3/31/2022
3/31/2021
3/31/2020
3/31/2019
Revenues34,15536,78632,26225,38117,9957,569
Cost of revenue(17,561)(19,250)(17,467)(13,514)(10,016)(4,701)
Gross profit:16,59417,53614,79511,8677,9792,868
Operating expenses(12,918)(11,574)(9,725)(9,763)(10,264)(12,026)
Operating income (loss):3,6765,9625,0712,105(2,285)(9,159)
Nonoperating income (expense)3105581,2342,04047(797)
Other nonoperating income (expense)    2,04047(797)
Interest and debt expense(1,113)(735)(192)(260)(356)(369)
Income (loss) from continuing operations before equity method investments, income taxes:2,8735,7846,1133,885(2,594)(10,325)
Other undisclosed income from continuing operations before income taxes1,113735192260356369
Income (loss) from continuing operations before income taxes:3,9866,5196,3044,145(2,238)(9,955)
Income tax expense (benefit)(424)(51)1,736  676
Other undisclosed income from continuing operations  1,736    
Income (loss) from continuing operations:3,5628,2058,0414,145(2,238)(9,279)
Income (loss) before gain (loss) on sale of properties:5,2358,0414,145(2,238)(9,908)
Loss from discontinued operations      (629)
Other undisclosed net loss     (2) 
Net income (loss):3,5628,2058,0414,145(2,240)(9,908)
Other undisclosed net income (loss) attributable to parent (87)857944 629
Net income (loss) available to common stockholders, basic:3,5628,1188,8985,088(2,240)(9,279)
Dilutive securities, effect on basic earnings per share(415)1,061(1,425)   
Other undisclosed net income (loss) available to common stockholders, diluted (1,425)  1,112(180)
Net income (loss) available to common stockholders, diluted:3,1477,7547,4735,088(1,129)(9,459)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
3/31/2023
12/31/2022
TTM
3/31/2022
3/31/2021
3/31/2020
3/31/2019
Net income (loss):3,5628,2058,0414,145(2,240)(9,908)
Comprehensive income (loss), net of tax, attributable to parent:3,5628,2058,0414,145(2,240)(9,908)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: